Medline (MDLN) Q4 Net Sales Rise 14.8% to $7.8B Following Completion of IPO

Medline Inc. (NASDAQ:MDLN) is one of the best NASDAQ stocks to buy according to hedge funds. On February 25, Medline reported its Q4 and full-year 2025 financial results, marking a significant year that included the completion of its initial public offering. For Q4, the company achieved net sales of $7.8 billion, representing a 14.8% increase driven by higher volumes in the Medline Brand and Supply Chain Solutions segments.

However, net income for the quarter fell by 37.7% to $180 million, while Adjusted EBITDA remained nearly flat at $805 million, impacted by higher operating costs, IPO-related expenses, and tariff-related costs of goods sold. The full year results showed a 11.5% increase in net sales to $28.4 billion, supported by $2.4 billion in new customer signings. While net income for the year decreased slightly by 3.6% to $1.2 billion due to investments in headcount and tariffs, Adjusted EBITDA grew by 3.2% to $3.5 billion.

Looking ahead, the CEO emphasized that the transition to a public company has strengthened Medline’s foundation for sustainable long-term growth. The company introduced 2026 guidance, projecting organic sales growth between 8% and 9%. Additionally, Medline Inc. (NASDAQ:MDLN) expects Adjusted EBITDA for 2026 to reach a range of $3.5 billion to $3.6 billion as it continues to utilize its distribution footprint and broad product portfolio.

Medline Inc. (NASDAQ:MDLN) manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the US and internationally. It operates through two segments: Medline Brand and Supply Chain Solutions.

While we acknowledge the potential of MDLN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 33 Stocks That Should Double in 3 Years.

Disclosure: None. Follow Insider Monkey on Google News.